Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
Aim: To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States. Methods: This large population-based, retrospective cohort study...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Clinical & Translational Endocrinology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623724000413 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124427807686656 |
|---|---|
| author | Arunkumar Krishnan Carolin V. Schneider Hendrik-Tobias Arkenau Ezequiel Matias Mauro Alejandro Forner W. Scott Butsch Declan Walsh Saleh A. Alqahtani |
| author_facet | Arunkumar Krishnan Carolin V. Schneider Hendrik-Tobias Arkenau Ezequiel Matias Mauro Alejandro Forner W. Scott Butsch Declan Walsh Saleh A. Alqahtani |
| author_sort | Arunkumar Krishnan |
| collection | DOAJ |
| description | Aim: To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States. Methods: This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA. Results: A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40–0.60) and DPP4Is (0.77, 95 % CI 0.67–0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk. Conclusions: GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA. |
| format | Article |
| id | doaj-art-7692fc64b12440d7bb080c8ee4890983 |
| institution | OA Journals |
| issn | 2214-6237 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical & Translational Endocrinology |
| spelling | doaj-art-7692fc64b12440d7bb080c8ee48909832025-08-20T02:34:19ZengElsevierJournal of Clinical & Translational Endocrinology2214-62372024-12-013810037010.1016/j.jcte.2024.100370Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort studyArunkumar Krishnan0Carolin V. Schneider1Hendrik-Tobias Arkenau2Ezequiel Matias Mauro3Alejandro Forner4W. Scott Butsch5Declan Walsh6Saleh A. Alqahtani7Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA; Department of Medicine, Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston Salem, NC, USA; Corresponding author at: The Center for Supportive Oncology, Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Suite 70100, Charlotte, NC 28204, USA.Department of Internal Medicine III, RWTH Aachen University, Aachen, GermanySarah Cannon Research Institute, Cancer Institute, University College London, London, UKBarcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, SpainBarcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, SpainBariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH, USADepartment of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USAOrgan Transplant Center of Excellence, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USAAim: To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States. Methods: This large population-based, retrospective cohort study using the TriNetX datasets included adult patients with type 2 diabetes mellitus (T2DM) who were new users of GLP-1RAs, DPP-4Is, or other second- or third-line antidiabetic drugs between 2010 and 2021. The primary outcome was the incidence of CCA. Results: A total of 3,816,071 patients were included (mean age, 61.4 years, female, 49.3 %). A 51 % and 23 % risk reduction in CCA after 1 year of exposure to GLP-1RAs (hazard ratio 0.49; 95 % CI 0.40–0.60) and DPP4Is (0.77, 95 % CI 0.67–0.90), respectively compared to new second-or third-line users. Results were consistent at 3, 5, and 7 years of follow-up (0.66, 0.71, and 0.72 for GLP-1RAs and 0.84, 0.87, and 0.85 for DPP-4Is, respectively). Compared to new metformin users, GLP-1RA users were associated with a 42 % lower risk of developing CCA, whereas DPP-4I group was not associated with an increased risk. Conclusions: GLP-1RAs and DPP-4Is were not associated with a significantly increased risk of CCA. GLP-1RAs even showed a reduced risk of CCA development. They can be considered as safe and effective treatment options for patients with T2DM at risk of CCA.http://www.sciencedirect.com/science/article/pii/S2214623724000413IncretinGlucagon-like peptide-1 receptor agonistsCholangiocarcinomaDipeptidyl peptidase 4 inhibitorsType 2 diabetes mellitus |
| spellingShingle | Arunkumar Krishnan Carolin V. Schneider Hendrik-Tobias Arkenau Ezequiel Matias Mauro Alejandro Forner W. Scott Butsch Declan Walsh Saleh A. Alqahtani Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study Journal of Clinical & Translational Endocrinology Incretin Glucagon-like peptide-1 receptor agonists Cholangiocarcinoma Dipeptidyl peptidase 4 inhibitors Type 2 diabetes mellitus |
| title | Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study |
| title_full | Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study |
| title_fullStr | Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study |
| title_full_unstemmed | Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study |
| title_short | Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study |
| title_sort | association between incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes a large population based matched cohort study |
| topic | Incretin Glucagon-like peptide-1 receptor agonists Cholangiocarcinoma Dipeptidyl peptidase 4 inhibitors Type 2 diabetes mellitus |
| url | http://www.sciencedirect.com/science/article/pii/S2214623724000413 |
| work_keys_str_mv | AT arunkumarkrishnan associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT carolinvschneider associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT hendriktobiasarkenau associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT ezequielmatiasmauro associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT alejandroforner associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT wscottbutsch associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT declanwalsh associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy AT salehaalqahtani associationbetweenincretinbaseddrugsandriskofcholangiocarcinomaamongpatientswithtype2diabetesalargepopulationbasedmatchedcohortstudy |